Chelsea Therapeutics Announces Reorganization Plan to Boost Stock Value

More news came out of Charlotte, N.C., Tuesday morning when beleaguered Chelsea Therapeutics (CHTP) announced its plans to undergo a complete reorganization of the company, which is to include layoffs, a new executive structure and changes to the Board of Directors, all with the long-term goal of developing more stockholder value, according to a press release.

The layoffs are expected to save the company $3.5 million in salaries over a year, and the layoffs should be completed by the end of the third quarter of 2012. Part of the plan includes not accepting any more patients for the company’s trial of the hypertension drug Northera, which should then produce results by the end of the year.

In other news, company founder, CEO and President Dr. Simon Pedder, announced that he was stepping down from the company effective immediately, and will serve only in an advisory capacity. The same is said for Keith Schmidt, vice president for marketing and sales, who is resigning his post but will remain an advisor to the company. During the search for a new CEO, Joseph G. Oliveto, VP for Operations for the last four years, will serve as interim CEO. In addition, three members of the Board of Directors (including Chairman Kevan Clemens) are stepping down.

While Chelsea is not widely held by hedge funds, this news may be very uncertain for Julian and Felix Baker’s Baker Bros. Advisors, which was invested nearly $5.9 million in Chelsea at the end of March. The next seven hedge funds combined were invested a total of less than $1 million.

“Chelsea Therapeutics has faced tremendous challenges in moving Northera forward through the regulatory process, making these difficult decisions necessary to ensure stockholder value is preserved in the short term and can be built over the long-term,” said Dr. Michael Weiser, the new Chairman of the Board in the wake of Clemens’ resignation, in a press release. ”We believe that this reorganization should allow the Company’s resources and capital to be laser-focused on efficient conclusion of the 306B study and the evaluation of next steps in the regulatory process. In tandem, the Board plans to explore and evaluate all available strategic options to determine the best path forward in the long-term strategic interests of the Company and its stockholders. We remain committed to Northera, a treatment which meets an important unmet need in patients and has a significant record of efficacy and safety in the clinic and in ex-U.S. markets. We would like to thank those employees leaving the Company for their service. We would also like to recognize Dr. Pedder’s years of dedication to Chelsea and his work in helping to advance the Company’s innovative therapies.”

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

The 20 Biggest Contracts in MLB History

The 7 Worst Blown Calls in Sports History

7 Free Ways to Advertise Your Business Online

The 18 Best R&B Songs of the 90’s

The 10 Most Dangerous States to be a Cop

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!